---
title: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (02196.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02196.HK.md"
symbol: "02196.HK"
name: "Shanghai Fosun Pharmaceutical (Group) Co.,Ltd."
industry: "Pharmaceuticals"
---

# Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (02196.HK)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | HK Market |
| Website | [www.fosunpharma.com](https://www.fosunpharma.com) |

## Company Profile

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous syste...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:10.000Z

**Overall: C (0.52)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 48 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.93% |  |
| Net Profit YoY | 53.77% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.04 |  |
| Dividend Ratio | 1.70% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 54.73B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 42.73B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.89% | C |
| Profit Margin | 8.30% | B |
| Gross Margin | 48.56% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -5.93% | D |
| Net Profit YoY | 53.77% | B |
| Total Assets YoY | 1.07% | C |
| Net Assets YoY | 1.32% | C |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1204.82% | B |
| OCF YoY | -5.93% | D |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.34 | D |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 48.52% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.89%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.30%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "48.56%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-5.93%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "53.77%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "1.07%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.32%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1204.82%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-5.93%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.34",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "48.52%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | HENGRUI PHARMA (HK.1276) | A | B | C | A | B | B |
| 02 | HANSOH PHARMA (HK.3692) | A | B | C | A | C | B |
| 03 | SINO BIOPHARM (HK.1177) | B | B | C | B | B | B |
| 04 | CMS (HK.867) | B | B | C | A | B | B |
| 05 | SIMCERE PHARMA (HK.2096) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.87 | 19/51 | 17.53 | 15.55 | 13.69 |
| PB | 1.02 | 19/51 | 1.14 | 1.02 | 0.79 |
| PS (TTM) | 1.24 | 14/51 | 1.39 | 1.23 | 0.90 |
| Dividend Yield | 1.74% | 23/51 | 1.97% | 1.72% | 1.55% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-04T16:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 50% |
| Overweight | 2 | 25% |
| Hold | 2 | 25% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.10 |
| Highest Target | 36.11 |
| Lowest Target | 24.66 |

## References

- [Company Overview](https://longbridge.com/en/quote/02196.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02196.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02196.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.